Brazil’s CMED approves price adjustment of medicines to 3.35%

4 April 2014

Brazil's National Health Surveillance Agency ANVISA’s office of pharmaceutical drug market regulation (CMED) has fixed the average price increase of medicines to a maximum of 3.35 % for 2014. This value is the lowest price increase approved by the CMED in the past five years, writes Juliane Carvalho on Brazil Pharma News.

The Resolution from the CMED's Council of Ministers with manufacturer ceiling price adjustment was published on March 27, 2014 in the Brazilian Official Gazette. Pharmaceutical companies and distributors can now sell medicines based on the approved new prices starting on March 31, 2014 as long as they follow the mandated rules in the CMED's pharmaceutical market report.

Regulation applies to over 9,000 drugs

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >